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Abstract
Objective
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treat-
ment of diabetes. We aimed at describing the maximal benefits and risks associated with
SGLT2-i for patients with type 2 diabetes.
Design
Systematic review and meta-analysis.
Data Sources and Study Selection
We included double-blinded, randomised controlled trials (RCTs) evaluating SGLT2-i
administered in the highest approved therapeutic doses (canagliflozin 300 mg/day, dapagli-
flozin 10 mg/day, and empagliflozin 25 mg/day) for12 weeks. Comparison groups could
receive placebo or oral antidiabetic drugs (OAD) including metformin, sulphonylureas (SU),
or dipeptidyl peptidase 4 inhibitors (DPP-4-i). Trials were identified through electronic data-
bases and extensive manual searches. Primary outcomes were glycated haemoglobin A1c
(HbA1c) levels, serious adverse events, death, severe hypoglycaemia, ketoacidosis and
CVD. Secondary outcomes were fasting plasma glucose, body weight, blood pressure,
heart rate, lipids, liver function tests, creatinine and adverse events including infections. The
quality of the evidence was assessed using GRADE.
Results
Meta-analysis of 34 RCTs with 9,154 patients showed that SGLT2-i reduced HbA1c com-
pared with placebo (mean difference -0.69%, 95% confidence interval -0.75 to -0.62%). We
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downgraded the evidence to ‘low quality’ due to variability and evidence of publication bias
(P = 0.015). Canagliflozin was associated with the largest reduction in HbA1c (-0.85%,
-0.99% to -0.71%). There were no differences between SGLT2-i and placebo for serious
adverse events. SGLT2-i increased the risk of urinary and genital tract infections and
increased serum creatinine, and exerted beneficial effects on bodyweight, blood pressure,
lipids and alanine aminotransferase (moderate to low quality evidence). Analysis of 12
RCTs found a beneficial effect of SGLT2-i on HbA1c compared with OAD (-0.20%, -0.28 to
-0.13%; moderate quality evidence).
Conclusion
This review includes a large number of patients with type 2 diabetes and found that SGLT2-i
reduces HbA1c with a notable increased risk in non-serious adverse events. The analyses
may overestimate the intervention benefit due bias.
Introduction
Patients with type 2 diabetes are characterized by hyperglycaemia with elevated levels of gly-
cated haemoglobin A1c (HbA1c) [1] which may lead to microvascular and macrovascular dis-
ease [2, 3]. Between 2012 and 2014, three sodium-glucose co-transporter 2 inhibitors
(SGLT2-i), canagliflozin, dapagliflozin and empagliflozin, were approved by the US Food and
Drug Administration (FDA) [4–6] and the European Medicines Agency (EMA) [7–10] for the
treatment of patients with type 2 diabetes. SGLT2-i inhibit glucose reabsorption in the proxi-
mal tubules of the kidneys, increasing urinary glucose excretion and reducing the amount of
circulating glucose [11]. SGLT2-i have been assessed as monotherapy or combined with other
antidiabetic agents including metformin, sulphonylureas (SU), dipeptidyl peptidase 4 inhibi-
tors (DPP-4-i), thiazolidinediones (pioglitazone) or insulin [12–19].
In 2015 the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD) recommend SGLT2-i as second-line agents in the management of
type 2 diabetes [20]. A recent randomised controlled trial (RCT) evaluated the effect of empa-
gliflozin on cardiovascular disease (CVD)-associated events in 7,020 patients with type 2 dia-
betes and a high risk of CVD events [21]. The study found that empagliflozin reduced the
relative risk of the CVD events including death from cardiovascular causes, non-fatal myocar-
dial infarction and non-fatal stroke by 14% (absolute risk reduction of 1.6%) compared to pla-
cebo. Whether the effect is specific for empagliflozin or represents a class effect for SGLT2-i
will be assessed in on-going RCTs assessing the effect of canagliflozin [22]. and dapagliflozin
[23] on CVD in patients with type 2 diabetes. However, the efficacy and safety of SGLT2-i in
patients with a low to moderate cardiovascular risk or in a real world setting, where patients
often have multiple co-morbidities and are treated with several drugs, have not been
established.
In contrast to previous meta-analyses evaluating the effects of SGLT2-i in type 2 diabetes,
we only included trials, which used the recommended maximum daily doses of the SGLT2-i
[24–36] as we expect these dosages to be the most widely used in the clinic [4–10]. Lower or
higher doses of SGLT2-i might overestimate or underestimate the efficacy or the risk of
adverse events. The present approach provides the evidenced-based clinician with a clear and
balanced summary of the existing evidence.
Effects of SGLT-2i in Patients with Type 2 Diabetes: A Meta-Analysis
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In addition, three studies found that intensive glucose lowering treatments may harm some
patients [37–39] and recently, the safety of SGLT2i was put into question by the regulatory
agencies [4–6, 8, 9].
We conducted the present systematic review with meta-analyses of RCTs evaluating the
safety and efficacy of the SGLT2-i canagliflozin, dapagliflozin, and empagliflozin administered
in highest clinically relevant doses for at least 12 weeks compared to placebo or OAD.
Methods
We conducted our review based on a published protocol (PROSPERO CRD42014008960; S2
File) [40] and adhered to the PRISMA standards [41] for the conduct and reporting of this sys-
tematic review and meta-analysis (PRISMA checklist; S3 File).
Search methods
Electronic searches were performed in the Cochrane Library, MEDLINE, EMBASE, the Sci-
ence Citation Index and the WHO Trial Search Database, using the following search string:
“((Sodium glucose (All Fields) AND co-transporter (All Fields)) OR (2-(3-(4-ethoxybenzyl)-
4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol (Supplementary Concept)
OR 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
(All Fields) OR dapagliflozin (All Fields)) OR (canagliflozin (Supplementary Concept) OR
canagliflozin (All Fields)) OR (empagliflozin (Supplementary Concept) OR empagliflozin (All
Fields))”. Additional manual searches were performed in reference lists of relevant papers. We
obtained additional data on e.g. heart rate, ALT and lipids from the study investigators, the
manufacturers and the YODA-project (details listed in S1 File) [42–45]. The last search update
was October 2015.
Trial eligibility and selection
We included English-language, full paper, double-blind RCTs conducted in adult patients (at
least 18 years of age) with type 2 diabetes. The interventions assessed were the recommended
daily target doses of the SGLT2-i canagliflozin 300 mg; dapagliflozin 10 mg; empagliflozin 25
mg [4–6, 8]. Controls could receive placebo or OAD including metformin, SU or DPP-4-i. We
only included RCTs with a treatment duration of at least 12 weeks. Co-interventions (‘add-on’
therapies) with other antidiabetic agents were allowed if administered to both the intervention
and control groups. We excluded studies, which involved participants with impaired kidney
function and SGLT-2i only approved in Japan (ipragliglozin, luseogliflozin, tofogliflozin) or in
clinical development (ertugliflozin, remogliflozin, sotagliflozin).
Trial selection was carried out by two review authors (HS and CB) who independently
reviewed the search results and selected trials for inclusion, with involvement of a third review
author (CB or TV) if necessary to resolve disagreements. Multiple publications, which
reported results from the same RCT, were grouped into ‘studies’ (S1 File).
Outcome variables and measures
Our primary outcomes were HbA1c (change from baseline) and serious adverse events defined
as the number of participants experiencing cancer (all cancers, bladder cancer, breast cancer),
death, severe hypoglycaemia, ketoacidosis and CVD. The secondary outcomes were fasting
plasma glucose (FPG) (mmol/L), change in body weight (kg), systolic and diastolic blood pres-
sure (SBP and DBP (mmHg)), heart rate (beats per minute (bpm)), plasma lipid profile (low-
density lipoprotein (LDL) cholesterol (mmol/L) (which is known to increase the risk of CVD),
Effects of SGLT-2i in Patients with Type 2 Diabetes: A Meta-Analysis
PLOS ONE | DOI:10.1371/journal.pone.0166125 November 11, 2016 3 / 23
high-density lipoprotein (HDL) cholesterol (mmol/L) and triglyceride (mmol/L)), alanine
amino transferase (U/L), adverse events leading to discontinuation and drug-related adverse
events. We also evaluated non-serious adverse events defined as the number of participants
experiencing urinary tract infections (UTI), genital tract infections (GTI); ’non-severe’ hypo-
glycaemia, and serum creatinine.
Data extraction and management
Trial characteristics (methods, participants, interventions, study outcomes, potential risks of
bias, and funding source) were recorded. Three authors (HS, MFG and MBC) independently
identified outcomes from each included study and extracted outcome data into extraction
forms (Excel spreadsheets). Consensus was reached through discussion. For trials presenting
data from more than one treatment period (e.g. 26 and 52 weeks), data from the longest treat-
ment period were used. For studies with multiple treatment arms for example SGLT2-i, other
OAD and placebo. We conducted separate evaluations and analyses of a) SGLT2-i versus pla-
cebo and b) SGLT2-i versus other OAD.
Assessment of risk of bias and quality
The bias risk assessment followed the Cochrane Collaboration’s risk of bias assessment tool.[46]
In each domain, studies were given a rating of low, unclear or high risk. We used the Grades of
Recommendation, Assessment, Development and Evaluation (GRADE) system to describe the
quality of the evidence and the strength of recommendation, ’high’ to ’very low’[47, 48].
Statistical analyses
We undertook meta-analyses in RevMan [49] using random-effects models, unless stated oth-
erwise. We chose the random-effects model due to an expected heterogeneity. We conducted
the analyses with the assumption that if the estimates were similar, then any small-study effects
had little effect on the intervention effect estimate. If the random-effects estimates were more
beneficial, we planned to re-evaluate whether it was reasonable to conclude that the interven-
tion was more effective in the smaller studies. However, in all of our analyses, the conclusions
of the fixed-effect and random-effects meta-analyses were consistent. Based on the expected
clinical heterogeneity, we expected that our analyses would display statistical between-trial het-
erogeneity (I2 > 0%). For random-effects models, precision will decrease with increasing het-
erogeneity and confidence intervals will widen correspondingly. We therefore (a priori)
planned to report the random-effects model under the assumption that they would provide
the most conservative (and a more correct) estimate of the intervention effect. We present
results as mean differences (MD) or relative risks (RR) with 95% confidence intervals (CI). For
effect sizes of MD, values greater than 0.70 were treated as large; values between 0.40 and 0.70
as moderate; and values less than 0.40 but greater than 0.10 as small.[46] We conducted sub-
group analyses on the basis of SGLT2-i type (canagliflozin, dapagliflozin, empagliflozin), and
on the basis of the type of OAD (metformin, SU, or DPP-4-i). Differences between subgroups
were reported using tests for subgroup differences expressed as P values. I2 values were used as
a measure of heterogeneity and are reported if they exceeded 30%. For meta-analyses with at
least 10 RCTs, publication bias and other small study effects were assessed in regression analy-
ses and funnel plots. For continuous variables, linear regression of the intervention effect esti-
mates on their standard errors, weighting by 1/(variance of the intervention effect estimate),
was used (Egger test). For dichotomous outcomes Z/sqrt(V) was regressed against sqrt(V)
(Harbord test), where Z is the efficient score and V is Fisher’s information (the variance of Z
under the null hypothesis).
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Results
Description of studies
We identified 1,087 potentially eligible records through our searches and included 42 RCTs
described in 59 published reports (Fig 1). The total number of participants was 24,500 (S1
File). Thirty-four RCTs compared SGLT2-i versus placebo and 12 compared SGLT2-i versus
OAD. Four RCTs were multi-arm, comparing SGLT2-i versus placebo and AD [17, 50–52].
Thirty-four RCTs compared SGLT2-i versus placebo. Seven RCTs evaluated canagliflozin
300 mg,[17, 50, 53–59] 17 evaluated dapagliflozin 10 mg,[12, 18, 19, 51, 60–79] and 10 evalu-
ated empagliflozin 25 mg[13–16, 52, 80–88] (Table 1). Twelve RCTs compared SGLT2-i versus
OAD (Table 1). Of these 12 trials, four compared canagliflozin versus glimepiride [89, 90] or
sitagliptin[17, 50, 91] and four compared dapagliflozin versus metformin [51, 92], glipizide
[93–95] or saxagliptin [96]. The remaining four studies compared empagliflozin versus lina-
gliptin [97, 98], glimepiride [99, 100] or sitagliptin [52]. The maximum doses of metformin
were 2000 mg [92] or 1500 mg [51]. The doses of the other OADs was 1 to 8 mg for glimepir-
ide, 20 mg for glipizide, 100 mg for sitagliptin, 5 mg for saxagliptin and 5 mg for linagliptin.
Thirty-one RCTs were multicentre and multinational carried out in USA, Europe and Asia
and three RCTs were conducted Japan [68, 69, 83]. The duration of the RCTs ranged from 12
weeks [17, 51, 56, 68, 70, 79–81, 83, 85] to 102 [53, 54, 57, 60–64, 72, 90, 99, 100], or 104 weeks
[53, 54], with the longest duration being 208 weeks [93–95].
Excluded studies
We excluded 17 RCTs (S1 File) for the following reasons: the dose used in the RCTs did not
meet our criteria, open label extension with optional cross-over of placebo, included patients
with kidney disease, was not double blind or assessed the combination of SGLT2-i and OAD
or insulin. We did not include any abstracts or RCTs published in other languages than
English.
Risk of bias
All RCTs had a low risk of bias in the assessment of randomisation (allocation sequence gener-
ation and concealment) and were double blind. One RCT was classified as unclear risk of attri-
tion bias [74]. The published trial report stated that “Approximately 93% of the patients in
each treatment arm completed the 24-week double-blind treatment period”. The description
of the statistical analyses explained that patients were excluded from the analyses if they did
not receive the intervention or did not have follow up assessments. We classified three RCTs
as unclear or high risk of reporting bias. One RCT did not provide a clear description of sec-
ondary/exploratory outcome measures [51]. The second RCT [70] listed the glomerular filtra-
tion rate as the only primary outcome in the registered trial protocol, but in the trial
publication, primary outcomes included renal function, blood pressure, and circulating plasma
volume. The third RCT did not provide information about adverse events [55]. All RCTs were
industry-funded and were classified as unclear risk of bias in the domain ‘other biases’.
Accordingly, none of the trials had a low risk of bias in all domains.
Change in HbA1c
Random-effects meta-analysis of 34 RCTs with 9,154 patients showed that SGLT2-i were asso-
ciated with a beneficial effect on HbA1c compared with placebo (MD -0.69%, CI -0.75 to
-0.62%, Fig 2). Between study heterogeneity was detected (I2 = 75%) and we found evidence of
small study effects in regression analysis (P = 0.015) and visual inspection of a funnel plot. In
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Fig 1. Flowchart for identification and selection of included trials. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flow chart.
doi:10.1371/journal.pone.0166125.g001
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Table 1. Characteristics of included randomised controlled trials comparing SGLT2-i versus placebo or other oral antidiabetic drugs (OAD).
Study ID Intervention Control Co-
intervention
Number
of
patients
Duration
(weeks)
Age
SGLT2-i
Age
control
BMI
SGLT2-i
BMI
control
HbA1c
SGLT2-i
HbA1c
control
Placebo controlled RCTs
Bode 2013[53,
54]
Canagliflozin
300 mg
Placebo Pre-existing
treatment
714 104* 63.4 63.2 31.5 31.8 7.7 7.8
Forst 2014[55] Canagliflozin
300 mg
Placebo Metformin,
pioglitazone
344 26 57 58.3 32.8 32.5 7.9 8.0
Gonzalez 2013
[50]
Canagliflozin
300 mg
Placebo Metformin 1,284 26 55.3 55.3 31.4 31.1 7.9 8.0
Inagaki 2013
[56]
Canagliflozin
300 mg
Placebo None 383 12 57.1 57.7 25.9 26.4 8.2 8.0
Rosenstock
2012[17]
Canagliflozin
300 mg
Placebo Metformin 451 12 52.3 53.3 31.6 30.6 7.7 7.8
Stenløf 2013
[57, 58]
Canagliflozin
300 mg
Placebo none 587 26 55.3 55.7 31.7 31.8 8 8
Wilding 2013
[59]
Canagliflozin
300 mg
Placebo Metformin, SU 469 78* 56.1 56.8 33.2 32.7 8.1 8.1
Bailey 2010
[60–62]
Dapagliflozin
10 mg
Placebo Metformin 546 102* 52.7 53.7 31.2 31.8 7.9 8.1
Bolinder 2012
[63, 64, 72]
Dapagliflozin
10 mg
Placebo Metformin 466 102* 60.6 60.8 32.1 31.7 7.2 7.2
Cefalu 2015
[65]
Dapagliflozin
10 mg
Placebo Insulin,
metformin
922 52* 62.8 63 32.6 32.9 8.2 8.1
Ferrannini
2010[12]
Dapagliflozin
10 mg
Placebo None 485 24 50.6 52.7 33.6 32.3 8.0 7.8
Jabbour 2014
[66]
Dapagliflozin
10 mg
Placebo Metformin,
sitagliptin
451 24 54.8 55 - - 7.9 8.0
Ji 2014[67] Dapagliflozin
10 mg
Placebo None 393 24 51.2 49.9 - - 8.3 8.4
Kaku 2013[68] Dapagliflozin
10 mg
Placebo None 279 12 56.5 58.4 - - 8.2 8.1
Kaku 2014[69] Dapagliflozin
10 mg
Placebo Not stated 261 24 57.5 60.4 26.1 25.2 7.5 7.5
Lambers
Heerspink
2013[70]
Dapagliflozin
10 mg
Placebo Metformin, SU 75 12 53.7 58 - - 7.7 7.5
Leiter 2014[71] Dapagliflozin
10 mg
Placebo Pre-existing,
treatment
964 52* 63.9 63.6 33 32.7 8.0 8.1
List 2009[51] Dapagliflozin
10 mg
Placebo None 389 12 54 53 31 32 8.0 7.9
Mathieu 2015
[73]
Dapagliflozin
10 mg
Placebo Saxagliptin
+ metformin
320 24 55.2 55 31.2 4.7 8.2 8.2
Matthaei 2015
[74, 75]
Dapagliflozin
10 mg
Placebo Metformin, SU 218 52* 61.1 60.9 31.9 32 8.1 8.2
Rosenstock
2012[76]
Dapagliflozin
10 mg
Placebo Pioglitazone 420 48** 53.8 53.5 - - 8.4 8.3
Strojek 2011
[77, 78]
Dapagliflozin
10 mg
Placebo Glimepiride 597 48* 58.9 60.3 - - 8.1 8.2
Wilding 2009
[79]
Dapagliflozin
10 mg
Placebo Metformin,
insulin,
pioglitazone,
rosiglitazone
71 12 55.7 58.4 35.5 34.8 8.4 8.4
(Continued )
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Table 1. (Continued)
Study ID Intervention Control Co-
intervention
Number
of
patients
Duration
(weeks)
Age
SGLT2-i
Age
control
BMI
SGLT2-i
BMI
control
HbA1c
SGLT2-i
HbA1c
control
Wilding 2012
[18, 19]
Dapagliflozin
10 mg
Placebo Insulin 108 48* 59.3 58.8 33.4 33.1 8.6 8.5
Ferrannini
2013[80, 81]
Empagliflozin
25 mg
Placebo None 408 12 57 58 28.3 28.8 7.8 7.8
Ha¨ring 2013
[13, 14]
Empagliflozin
25 mg
Placebo Metformin, SU 669 76* 57.4 56.9 28.3 27.9 8.1 8.2
Haring 2014
[82, 84]
Empagliflozin
25 mg
Placebo Metformin 638 76* 55.6 55.5 29.7 28.7 7.9 7.9
Kadowaki 2014
[83]
Empagliflozin
25 mg
Placebo None 547 12 57.3 58.7 25.1 25.6 7.9 7.9
Kovacs 2014
[15, 16]
Empagliflozin
25 mg
Placebo Metformin,
pioglitazone
499 76* 54.2 54.6 29.1 29.3 8.1 8.2
Roden 2013
[52]
Empagliflozin
25 mg
Placebo None 899 24 53.8 54.9 28.2 28.7 7.9 7.9
Rosenstock
2013[85]
Empagliflozin
25 mg
Placebo Metformin 495 12 59 60 31.5 31.3 8.1 8.0
Rosenstock
2014[86]
Empagliflozin
25 mg
Placebo Insulin +/-
metformin
563 52 58 55.3 35 34.7 8.3 8.3
Rosenstock
2015[87]
Empagliflozin
25 mg
Placebo Insulin +/-
metformin and
SU
494 78 59.9 58.1 32.7 31.8 8.1 8.3
Ross 2015[88] Empagliflozin
25 mg
Placebo Metformin 983 16 58.1 57.9 32.1 32 7.7 7.7
RCTs with OAD control
Cefalu 2013
[89, 90]
Canagliflozin
300 mg
Glimepiride 8
mg
Metformin 1,452 104* 55.8 56.3 31.2 30.9 7.8 7.8
Gonzalez 2013
[50]
Canagliflozin
300 mg
Sitagliptin
100 mg
Metformin 1,284 26 55.3 55.5 31.4 32 7.9 7.9
Rosenstock
2012[17]
Canagliflozin
300 mg
Sitagliptin
100mg
Metformin 451 12 52.3 51.7 31.6 31.6 7.7 7.6
Schernthaner
2013[91]
Canagliflozin
300 mg
Sitagliptin
100 mg
Metformin, SU 755 52* 56.6 56.7 31.5 31.7 8.1 8.1
Henry 2012[92] Dapagliflozin
10 mg
Metformin
1500 mg
None 641 24 51.1 52.7 - - 9.1 9.1
List 2009[51] Dapagliflozin
10 mg
Metformin
2000 mg
None 389 12 54 54 31 32 8.0 7.9
Nauck 2011
[93–95]
Dapagliflozin
10 mg
Glipizide 20
mg
Metformin 814 208 58 59 31.7 31.2 7.7 7.7
Rosenstock
2015[96]
Dapagliflozin
10 mg
Saxagliptin5
mg
Metformin 534 24 54 55 31.5 31.8 8.9 9.0
DeFronzo
2015[97]
Empagliflozin
25 mg
Linagliptin 5
mg
Metformin 899 52* 55.5 56.2 31.8 30.6 8.0 8.0
Lewin 2015[98] Empagliflozin
25 mg
Linagliptin5
mg
None 686 52* 56 53.8 31.2 31.9 8.0 8.1
Ridderstråle
2014[99, 100]
Empagliflozin
25 mg
Glimepiride1
to 4 mg
Metformin 1,549 104* 56.2 55.7 30 30.3 7.9 7.9
Roden 2013
[52]
Empagliflozin
25 mg
Sitagliptin
100 mg
None 677 24 53.8 55.1 28.2 28.2 7.9 7.9
BMI, body mass index (kg/m2); HbA1c, glycated haemoglobin A1c (%); SU, suphonylureas; RCTs, randomised controlled trials.
doi:10.1371/journal.pone.0166125.t001
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addition, subgroup analysis showed a clear difference between subgroups (test for subgroup
differences P = 0.008). The largest effect size was seen for canagliflozin (-0.85%, -0.99 to
-0.71%; Fig 2).
Fig 2. Change in glycated haemoglobin: forest plot of randomized controlled trials comparing
sodium-glucose co-transporter 2 inhibitors (SGLT2-i) versus placebo. The plot shows subgroups of
trials assessing the different SGLT2-i.
doi:10.1371/journal.pone.0166125.g002
Effects of SGLT-2i in Patients with Type 2 Diabetes: A Meta-Analysis
PLOS ONE | DOI:10.1371/journal.pone.0166125 November 11, 2016 9 / 23
Analyses of 12 RCTs showed that SGLT2-i were associated with a larger reduction in
HbA1c than OAD (-0.20%, -0.28–0.13%; Fig 3). There was between study heterogeneity, evi-
dence of small study effects (P = 0.0385), and no difference between subgroups of trials strati-
fied by the OAD (P = 0.11). We found no difference in HbA1c-reduction between SGLT2-i
and metformin (-0.05%, 0.21 to 0.12%, Fig 3), but a larger HbA1c reducing effect of SGLT2-i
compared with SU (-0.15%, -0.21 to -0.08%) and DPP-4-i (-0.25%, -0.36 to -0.14%).
Serious adverse events
Only a few serious adverse events were recorded and no differences were seen between
SGLT2-i versus placebo (RR 0.99, CI 0.87 to 1.12, 34 RCTs, 10,703 patients) or OAD (1.02,
0.78 to 1.34, 12 RCTs, 6,759 patients). Five patients randomized to SGLT2-i and six patients
randomized to placebo reported severe hypoglycaemia (0.75, 0.23 to 2.43, n = 5,077 patients).
Fig 3. Change in glycated haemoglobin: forest plot of randomized controlled trials comparing sodium-
glucose so-transporter 2 inhibitors (SGLT2-i) versus oral antidiabetic drugs (OAD). The plot shows
subgroups of trials assessing the different OAD.
doi:10.1371/journal.pone.0166125.g003
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In trials comparing SGLT2i versus SU, no patients versus three patients experienced a severe
hypoglycaemic event (0.13, 0.02 to 0.73, n = 814). No cases of ketoacidosis were reported. In
total, 32 of 3,201 patients allocated to SGLT2-i and 29 of 3,223 allocated to placebo developed
cancers (1.04, 0.6 to 1.83; 19 RCTs). Only one case of bladder cancer was reported, in the pla-
cebo arm of a dapagliflozin study [71]. Six of 2,767 patients were diagnosed with breast cancer
in the SGLT2-i arms compared with two of 2,789 patients in the placebo arms (1.73, 0.56 to
5.36; 18 RCTs). When analysing RCTs comparing SGLT2-i with other OAD, seven patients
allocated to canagliflozin and three allocated to sitagliptin were diagnosed with other types of
cancer than bladder or breast cancer (2.41, 0.69 to 8.37; 2 RCTs). One patient allocated to
canagliflozin developed breast cancer [50] and none developed bladder cancer.
CVD events were recorded in 56 of 5,438 patients randomized to SGLT2-i versus 45 of
5,263 randomized to placebo (1.24, 0.86 to 1.81) or OAD (0.78, 0.27 to 2.32).
Secondary outcomes
FPG. As shown in Table 2, analysis of 33 RCTs with 8,914 patients found that FPG levels
were 0.9 mmol/L lower in the SGLT2-i arm compared with the placebo arm (-1.0 to -0.8
mmol/L). There was no small study effect (P = 0.122) and a difference between subgroups (P =
0.04). The largest effect size was seen for canagliflozin (Table 2).
We found no difference between SGLT2-i and metformin [51, 92] or SU [57, 90, 93–95, 99,
100] but a beneficial effect compared with DPP-4-i (-1.0, 1.3 to 0.7 mmol/L, Table 3) [17, 50,
52, 91, 96–98]. The between trial heterogeneity was moderate to high in all analyses.
Bodyweight loss. SGLT2-i were associated with a loss of body weight compared with pla-
cebo (-2.1 kg, -2.3 to -2.0 kg). The effect was different in subgroups stratified by the type of
SGLT2-i (P < 0.01) with the largest weight reduction associated with canagliflozin (Table 2).
SGLT2-i also reduced the body weight compared to OAD (Table 3).
Blood pressure and heart rate. SGLT2-i reduced the systolic blood pressure compared
with placebo (-3.9 mmHg, -4.6 to -3.3 mmHg), there were subgroup differences (P = 0.03),
with the largest effect seen for canagliflozin (Table 2). SGLT2-i also reduced the systolic blood
pressure compared with OAD (Table 3). A similar effect was seen in analyses of the diastolic
blood pressure (Tables 2 and 3). The heart rate did not differ between patients allocated to
SGLT2-i versus placebo (-0.6 bpm, -1.3 to 0.0 bpm) (Table 3). However, there was a difference
between subgroups when compared with placebo (P = 0.04) and empagliflozin induced a mod-
est increase in heart rate (Table 2). The heart rate in the SGLT2-i group was lower than in the
DPP-4-i group (-1.50 bpm, 2.7 to 0.4 bpm).
Lipids. SGLT2-i was associated with increased HDL cholesterol compared with placebo
(0.05 mmol/L, 0.04 to 0.07 mmol/L). A similar result was achieved for LDL cholesterol (0.09
mmol/L, 0.04 to 0.14 mmol/L), whereas triglyceride decreased (-0.09 mmol/L, -0.16 to -0.02
mmol/L). Subgroup analysis showed a difference between subgroups, with the largest effects
seen for canagliflozin on HDL cholesterol, LDL cholesterol and triglycerides (Table 2).
SGLT2-i increased HDL and LDL cholesterol, but did not reduce triglycerides compared to
OAD (SU and DPP-4-i) (Table 3).
Liver function blood tests. Analyses of 18 RCTs with 3,719 patients found evidence that
SGLT2-i reduced alanine aminotransferase levels compared with placebo (-2.8 U/L, CI -4.0 to
-1.7 U/L) or OAD (Table 3).
Serum creatinine. STLG2-i were associated with a 0.60 μmol/L increase in creatinine
compared with placebo (0.1 to 1.1 μmol/L) (Table 2). The largest increase was seen for canagli-
flozin. Analysis of SGLT2-i versus other OAD showed no difference between SGLT2-i and
metformin or DPP-4-i (Table 3).
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Table 2. Number of included patients, mean difference and heterogeneity in meta-analyses of double blind, randomised controlled trials compar-
ing SGLT2-i versus placebo.
SGLT2-i Total n Mean difference(confidence interval) I2(Q)% Subgroup differences
Fasting plasma glucose (mg/dL) 8,914 -28.1 (-31.1; -25.1) 79.1 P = 0.04
Body weight (kg) 9,612 -2.1 (-2.3; -2.0) 44.5 P < 0.01
Systolic blood pressure (mmHg) 9,336 -3.9 (-4.6; -3.3) 33.6 P = 0.03
Diastolic blood pressure (mmHg) 7,402 -2.0 (-2.4; -1.6) 6.3 P = 0.82
Heart rate (bpm) 4,587 -0.6 (-1.3; 0.0) 48.4 P = 0.04
HDL cholesterol (mmol/L) 4,698 0.05 (0.04; 0.07) 31.0 P = 0.03
Triglycerides (mmol/L) 4,704 -0.09 (-0.16; 0.02) 29.8 P < 0.01
LDL cholesterol (mmol/L) 5,431 0.09 (0.04; 0.14) 55.5 P < 0.01
Alanine aminotransferase (U/L) 3,719 -2.8 (-4.0; -1.7) 44.3 P = 0.59
Creatinine (μmol/L) 5,445 0.6 (0.1; 1.1) 11.3 P = 0.05
Canagliflozin Total n MD (CI) I2(Q)%
Fasting plasma glucose (mg/dL) 2,115 -34.0 (-40.4; -27.6) 77
Body weight (kg) 2,117 -2.6 (-2.9; -2.3) 21
Systolic blood pressure (mmHg) 2,208 -5.4 (-6.8; -4.0) 42
Diastolic blood pressure (mmHg) 2,208 -2.1 (-2.8; -1.5) 0
Heart rate (bpm) 1,336 -1.0 (-1.1; -0.9) 0
HDL cholesterol (mmol/L) 2,088 0.07 (0.06; 0.09) 0
Triglyceride (mmol/L) 2,094 -0.21 (-0.30; -0.12) 0
LDL cholesterol (mmol/L) 2,086 0.19 (0.11; 0.26) 31
Alanine aminotransferase (U/L) 1,229 -3.5 (-5.8; -1.2) 67
Creatinine (μmol/L) 1,238 1.8 (0.7; 2.9) 13
Dapagliflozin Total n MD (CI) I2(Q)%
Fasting plasma glucose (mg/dL) 3,844 -24.6 (-28.7; -20.4) 74
Body weight (kg) 4,432 -2.0 (-2.2; -1.8) 24
Systolic blood pressure (mmHg) 3,943 -3.5(-4.3; -2.7) 1
Diastolic blood pressure (mmHg) 2,009 -2.1 (-2.9; -1.3) 8
Heart rate (bpm) 2,148 -0.7 (-2.1; 0.7) 63
HDL cholesterol (mmol/L) 175 0.09 (-0.03; 0.21) NA
Triglyceride (mmol/L) 175 0.00 (-0.12; 0.12) NA
LDL cholesterol (mmol/L) 175 -0.15 (-0.32; 0.02) NA
Alanine aminotransferase (U/L) 1,817 -2.1 (-3.8; -0.5) 30
Creatinine (μmol/L) 2,335 0.3 (-0.4; 1.0) 0
Empagliflozin Total n MD (CI) I2(Q)%
Fasting plasma glucose (mg/dL) 2,955 -29.5 (-33.1; -25.9) 60
Body weight (kg) 3,063 -2.0 (-2.2; -1.7) 9
Systolic blood pressure (mmHg) 3,185 -3.2 (-4.2; -2.3) 11
Diastolic blood pressure (mmHg) 3,185 -1.9 (-2.5; -1.2) 31
Heart rate (bpm) 1,103 0.5 (-0.7; 1.6) 0
HDL cholesterol (mmol/L) 2,417 0.04 (0.02; 0.06) 27
Triglyceride (mmol/L) 2,435 0.00 (-0.09; 0.08) 0
LDL cholesterol (mmol/L) 3,173 0.06 (0.01; 0.10) 0
Alanine aminotransferase (U/L) 673 -3.4 (-6.1; -0.6) 46
Creatinine (μmol/L) 1,872 0.3 (-0.6; 1.1) 15
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SU, sulphonylureas; DPP-4-i, dipeptidyl peptidase 4 inhibitors; The difference between SGLT2-i
was assessed using a test for subgroup differences (reported using P-values)
doi:10.1371/journal.pone.0166125.t002
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Non-serious adverse events. Compared with placebo, SGLT2-i were associated with an
increased risk of UTI (1.14, 1.0 to 1.3) and GTI (4.34, 3.35 to 5.63). SGLT2-i were also associ-
ated with an increased risk of UTI compared with metformin (2.01, 1.01, 3.98), but not SU
(1.05, 0.84 to 1.31) or DPP-4-i (0.89, 0.67 to 1.19). SGLT2-i were associated with an increased
risk of GTI compared with metformin (4.48, 1.76 to 11.42), SU (5.41, 3.64 to 8.03) and DPP-
4-i (3.69, 2.42 to 5.63; P < 0.00001).
An analysis of 33 RCTs with 10,440 patients found fewer episodes of non-severe hypogly-
caemia in the placebo group compared to the SGLT2-i group (1.11, 1.03 to 1.2). Subgroup
analysis showed a difference between subgroups (P = 0.04). The largest risk of hypoglycaemia
was seen for canagliflozin (1.53, 1.15 to 2.03). Dapagliflozin (1.07, 0.95 to 1.19) and empagliflo-
zin (1.03, 0.9 to 1.19) did not increase the risk of non-severe hypoglycaemia. SGLT2-i were
associated with a decreased risk of non-severe hypoglycaemia compared with SU (0.16, 0.11,
0.22), but not compared with metformin (0.5, 0.18 to 1.43) or DPP-4-i (1.00, 0.49 to 2.02). In
the SGLT2-i group, more participants experienced drug-related adverse effects (1.45, 1.27 to
1.66) and discontinued treatment (1.28, 1.08 to 1.51) compared with placebo.
Table 3. Number of included patients, mean difference and heterogeneity in meta-analyses of double blind, randomised controlled trials compar-
ing SGLT2-i versus oral antidiabetic drugs.
SGLT2-i versus metformin Total n MD (CI) I2(Q)%
Fasting plasma glucose (mmol/L) 526 -0.3 (-0.5; 0.0) 54.7
Body weight (kg) 530 -1.3 (-1.8; -0.7) 0.0
Systolic blood pressure (mmHg) 467 -3.8 (-6.8; -0.9) 28.5
Diastolic blood pressure (mmHg) 467 -1.9 (-3.3; -0.6) 0.0
Heart rate (bpm) 467 -0.7 (-2.2; 0.8) 0.0
Alanine aminotransferase (U/L) 457 -3.6 (-6.4; -0.7) 0.0
Creatinine (μmol/L) 456 0.3 (-1.5; 2.1) 0.0
SGLT2-i versus SU Total n MD (CI) I2(Q)%
Fasting plasma glucose (mmol/L) 2,664 -0.2 (-0.5; 0.1) 93.3
Body weight (kg) 2,811 -4.4 (-4.7; -4.1) 0.0
Systolic blood pressure (mmHg) 2,804 -5.0 (-6.0; -4.0) 18.3
Diastolic blood pressure (mmHg) 2,505 -2.5 (-3.1, -2.0) 0.0
HDL cholesterol (mmol/L) 2,478 0.10 (0.08; 0.12) 0.0
Triglyceride (mmol/L) 2,478 -0.06 (-0.15; 0.02) 0.0
LDL cholesterol (mmol/L) 2,477 0.16 (0.11; 0.21) 0.0
Creatinine (μmol/L) 1,500 -2.0 (-3.1; -0.9) n/a
SGLT2-i versus DPP-4-i Total n MD (CI) I2(Q)%
Fasting plasma glucose (mmol/L) 2,813 -0.6 (-0.7; -0.4) 76.6
Body weight (kg) 2,877 -2.5 (-2.6; -2.3) 0.0
Systolic blood pressure (mmHg) 2,884 -3.8 (-4.8; -2.7) 31.5
Diastolic blood pressure (mmHg) 2,884 -1.8 (-2.4; -1.2) 15.1
Heart rate (bpm) 1,995 -1.5 (-2.6; -0.4) 53.8
HDL cholesterol (mmol/L) 2,039 0.08 (0.06; 0.10) 0.0
Triglyceride (mmol/L) 2,047 -0.06 (-0.20; 0.09) 81.4
LDL cholesterol (mmol/L) 2,483 0.13 (0.07; 0.19) 0.0
Alanine aminotransferase (U/L) 1,571 -3.6 (-6.6; -0.6) 80.4
Creatinine (μmol/L) 2,150 -0.2 (-0.9; 0.6) 0.0
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SU, sulphonylureas; DPP-4-i, dipeptidyl peptidase 4 inhibitors.
doi:10.1371/journal.pone.0166125.t003
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Quality of the evidence
We gave evidence from RCT data a high quality rating, but downgraded it if there was unex-
plained clinically important heterogeneity, the study methodology had a risk of bias, the evi-
dence was indirect, there was important uncertainty around the estimate of effect, or there was
evidence for reporting bias. Therefore, it was possible for RCT data to have a very low quality
of evidence if several of these concerns were present. Where we downgraded the evidence, it
was mainly because there was risk of bias, small study effects, or considerable heterogeneity.
Some outcomes had relatively few events (e.g. mortality) and wide CIs (imprecision). The
results of many meta-analyses had moderate to high levels of statistical heterogeneity (incon-
sistency). The heterogeneity between the trials resulted from differences between the three
SGLT2-i and in the outcome measures reported, the duration of follow up and the trials inclu-
sion criteria. In the assessment of the primary outcomes, we downgraded the quality of the evi-
dence for glycated haemoglobin in the analyses comparing SGLT2-I by two levels to low
quality, due to heterogeneity and evidence of publication bias or other small study effects. We
also downgraded the outcome serious adverse events and analyses comparing SGLT2-i versus
OAD to moderate quality evidence due to uncertainty (wide confidence intervals) and hetero-
geneity, respectively.
Discussion
The highest approved doses of canagliflozin, dapagliflozin and empagliflozin compared with
placebo, were effective in reducing HbA1c in patients with type 2 diabetes. In spite of the large
number of RCTs with a low risk of bias in several domains, we downgraded the evidence to
low quality. Based on our assessment of publication bias and other smalls study effects, we
found evidence of bias and therefore a risk that the analyses overestimate the intervention ben-
efit. In the included RCTs, SGLT2-i had no discernible beneficial or harmful effects on serious
adverse events including mortality, cancer, ketoacidosis, severe hypoglycaemia, bladder can-
cer, breast cancer or other cancer types. SGLT2-i also had no effect on CVD events, but
SGLT2-i were associated a beneficial effect on CVD-associated risk factors including body
weight, blood pressure and lipids (although elevations in LDL lipids may be a concern). As
expected, SGLT2-i increased the risk of non-serious adverse events, including serum creati-
nine levels, UTI and GTI. Additional meta-analyses showed similar effects, when comparing
SGLT2-i versus other OAD, but the analyses with active comparators included a smaller num-
ber of trials and patients. We also identified important potential limitations, which mainly
included a high degree of inconsistency. The inconsistency is likely to reflect clinical heteroge-
neity in terms of the interventions, populations and follow-up times. Furthermore, selective
reporting of outcomes (e.g. CVD, cancer etc.) may also bias the estimates. Therefore, it is pos-
sible that the true effect differs somewhat from the estimated effects.
We found statistically clear differences between SGLT2-i in subgroup analyses. The largest
effect was seen for canagliflozin in the analyses of HbA1c and CVD-related risk factors. How-
ever, none of the trials compared the individual SGLT2-is and the results, therefore, remain
exploratory. Thus, the lack of head-to-head comparisons between the SGLT2-i means that we
cannot exclude the possibility that the difference between SGLT2-i reflect patient inclusion cri-
teria rather than a true difference between intervention effects.
Patients with type 2 diabetes have a high risk of adverse CVD outcomes [101]. The effects
of SGLT2-i on cardiovascular mortality and morbidity in patients with type 2 diabetes are
unknown. In one study [21], empagliflozin was associated with a lower rate of cardiovascular
events compared with placebo. Despite a sample size of more than 24,500 patients in this
review, few RCTs reported CVD as an outcome. In our analyses of CVD events, we found no
Effects of SGLT-2i in Patients with Type 2 Diabetes: A Meta-Analysis
PLOS ONE | DOI:10.1371/journal.pone.0166125 November 11, 2016 14 / 23
differences between SGLT2-i and placebo or OAD. We only found beneficial effect on out-
comes that may be associated with a lower risk of CVD.
We found a beneficial effect of SGLT2-i on alanine aminotransferase, which is associated
with non-alcoholic fatty liver disease in the early phase. Increasing evidence suggests that non-
alcoholic fatty liver disease may increase the risk of CVD [102–104]. SGLT2-i decreased ala-
nine aminotransferase both in comparison to placebo and OAD. While such improvements
may be attributed solely to weight loss, rather than drug-specific effects [105] additional evi-
dence is needed to determine the potential clinical implications of the findings.
We included creatinine, which may reflect dehydration due to the glycosuria. On SGLT2-i,
approximately 500 ml of water after treatment is initiated [106]. The loss generally decreases
during long term treatment. Increased serum creatinine may although reflect a worsening of
kidney function which is predictive of CVD [107–109]. The largest increase in creatinine levels
was found in RCTs evaluating canagliflozin. Whether this translates to an increased risk of
CVD events in patients taking SGLT2-i over the long-term is unclear.
Recently, ketoacidosis has been reported as an adverse effect of SGLT2-i [110]. The RCTs
in this review did not routinely report ketoacidosis as an outcome. Theoretically, there is a
potential for developing ketoacidosis as a result of the insulin-independent glucose excretion
combined with increased glucagon levels [111]. However, a recent large RCT [21] has found a
low incidence of ketoacidosis ( 0.1%) and that the risk was similar in patients treated with
empagliflozin and placebo.
SGLT2-i are widely studied and several reviews and meta-analyses have recently been pub-
lished [34–36]. Compared to these studies our systematic review with meta-analysis has dis-
tinct differences in the dosages and outcomes that we address. Zaccardi et al. performed a
network meta-analysis that focused on efficacy and safety of SGLT2-i [34]. In contrast to our
meta-analysis, they included trials with several different doses of canagliflozin, dapagliflozin
and empagliflozin and they reported fewer secondary outcomes than us (we also include e.g.
ALT, Creatinine and heart rate). In another meta-analysis, Wu et al. examined the effects of
SGLT2-i on cardiovascular events, death and major safety outcomes in adults with type 2 dia-
betes [35]. No beneficial effects of SGLT2-i were reported. We analysed both efficacy and
safety data. In the network meta-analysis by Shyangdan et al., the primary aim was to compare
the efficacy of SGLT2-i [36]. The investigators only included trials on SGLT2-i in monother-
apy or as add on to metformin in patients with type 2 diabetes. Only a total of 10 trials were
included and no data on adverse events were provided.
Future RCTs would ideally be long-lasting and large-scale comparing SGLT2-i with placebo
or existing therapies. Such RCTs should additionally include reporting of serious adverse
events such as CVD risk, ketoacidosis and severe hypoglycaemia, and monitoring of renal
safety, with adequate follow-up (over one year), to establish the long-term consequences of
SGLT2-i therapy.
Conclusion
Based on our review we found evidence that clinically relevant doses i.e. the recommended
daily target doses of SGLT2-i that are included in this review, during more than 12 weeks
reduce HbA1c levels in patients with type 2 diabetes compared with placebo and other existing
oral therapies. We planned to include high-quality RCTs with clinically relevant doses and suf-
ficient follow up to generate an estimate based on the best available evidence. However, our
analyses showed evidence of bias and heterogeneity. Likewise, the incidence of serious adverse
events including mortality, CVD and cancer was not increased as a result of SGLT2-i, but
reporting was inconsistent. Several CVD risk factors such as obesity, blood pressure and HDL
Effects of SGLT-2i in Patients with Type 2 Diabetes: A Meta-Analysis
PLOS ONE | DOI:10.1371/journal.pone.0166125 November 11, 2016 15 / 23
cholesterol may be improved by SGLT2-i therapy, whereas the incidences of UTI and GTI are
increased in the SGLT2-i groups. Additional evidence may therefore be needed to determine
the benefit and safely of SGLT2-i. The RCTs included in our review were largely carried out in
research hospital settings. Given the high prevalence of type 2 diabetes in the general popula-
tion, RCTs conducted outside the hospital settings seem warranted.
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